98%
921
2 minutes
20
The relationship between the frailty index (FI) and all-cause mortality in patients with kidney stones remains unclear, and whether this relationship is mediated by the systemic Immune-Inflammation index (SII). This cohort study analyzed data from the National Health and Nutrition Examination Survey (NHANES) in the United States, spanning 2007 to 2018. Utilizing Kaplan-Meier survival curves, Cox regression analysis, restricted cubic splines (RCS), and mediation analysis, the research investigated the relationships between FI, SII, and all-cause mortality in individuals with kidney stones. During a median follow-up of 6.3 years (16695 person-years) ,356 total deaths were recorded. A cohort of 2,620 U.S. participants was enrolled from NHANES 2007-2018. Frail individuals demonstrated significantly higher all-cause mortality compared to non-frail counterparts (HR = 1.78, 95% CI: 1.56-2.02, P < 0 0.001). Among patients with kidney stones, the FI showed a positive correlation with the SII (β = 38.18, 95% CI: 10.38-65.99, P < 0.01). The SII indirectly influenced the FI and all-cause mortality in these patients, accounting for 5.6% of the mediating effect. Among U.S. adults with kidney stones, the FI is linked to a higher risk of all-cause mortality, with SII potentially serving as a biological mechanism.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399735 | PMC |
http://dx.doi.org/10.1007/s00240-025-01837-7 | DOI Listing |
Diabetes Metab Syndr Obes
September 2025
Department of Nephrology, Wuyi County First People's Hospital, Jinhua City, Zhejiang Province, People's Republic of China.
Purpose: Metabolic syndrome (MetS) is linked to adverse outcomes in chronic diseases, but its impact on acute kidney injury (AKI) in elderly critically ill patients remains unclear. This study aimed to evaluate the association between MetS and 90-day mortality in this population.
Patients And Methods: A retrospective analysis included 774 elderly patients (≥65 years) with AKI admitted to the ICU from January 2022 to December 2023.
ERJ Open Res
September 2025
Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background: In Belgium, age-standardised hospital admission and mortality rates for asthma and COPD are higher than the European average. Understanding the factors that lead to a hospitalised exacerbation and/or mortality is needed to optimise patient management.
Methods: Patients ≥18 years old obtaining two claims for drugs for obstructive airway diseases (ATC code R03) in 1 year between 2017 and 2022 were identified in Belgian nationwide claims-based data.
Eur Heart J Open
September 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Aims: Intravenous tolvaptan sodium phosphate (IV-tolvaptan) is a novel aquaretic agent for acute decompensated heart failure (ADHF). This study evaluated its short-term effects and prognostic implications in clinical practice.
Methods And Results: In this retrospective cohort of 169 consecutive ADHF patients receiving IV-tolvaptan for the first time (mean age 76.
Eur Heart J Open
September 2025
Calderdale and Huddersfield NHS Foundation Trust, Acre St, Lindley, Huddersfield HD3 3EA, UK.
Aims: Cardiogenic shock remains a significant cause of mortality despite multiple advancements in medical interventions. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides crucial circulatory support but also increases left ventricular (LV) after-load, potentially worsening outcomes. Effective LV unloading strategies can enhance patient survival during VA-ECMO treatment.
View Article and Find Full Text PDFEur Heart J Open
September 2025
Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Gentofte Hospitalsvej 8, 2900 Hellerup, Denmark.
Aims: Atrial fibrillation (AF) may be associated with adverse influenza-related outcomes. We assessed the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) vs. standard-dose (SD-IIV) inactivated influenza vaccination against cardiovascular and all-cause hospitalizations and all-cause mortality according to history of AF.
View Article and Find Full Text PDF